Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breast cancer patients who received letrozole with or without bevacizumab
- Citation:
- Clin. Cancer Res. vol 26 (18) 4911-4920
- Year:
- 2020
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 10
- Parents:
- 3076
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Genentech
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233373, U10CA180820 (EA), UG1CA233329, U10CA180888 (SWOG)
- Corr. Author:
- Authors:
- Mark Jesus M. Magbanua Oleksandr Savenkov Erik J. Asmus Karla V. Ballman Janet H. Scott John W. Park Maura Dickler Ann Partridge Lisa Carey Eric Winer Hope S. Rugo
- Networks:
- AURORA, CA136, LAPS-CT018, LAPS-MA036, LAPS-NC007, LAPS-NY016
- Study
- CALGB-40503
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- circulating tumor cells, hormone receptor-positive, metastatic breast cancer, bevacizumab, letrozole